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Background. Although hepatocellular carcinoma (HCC) is one of the most common malignancy related 
mortality worldwide, it can be curable if detected in early stages. Emergence of a new marker that can early detect 
HCC could help in early treatment and therefore ameliorate the outcome. 
Objective. The aim of the research is to evaluate the performance of serum soluble CD25 (sCD25) in the 
prediction of early HCC and compare it to α-fetoprotein (AFP). 
Methods. Serum levels of sCD25 and AFP were measured in three groups of population; HCC group (40 
patients), cirrhosis without HCC control group (20 patients) and healthy control group (20 patients). HCC group 
contained 20 early and 20 late stage patients according to Barcelona Clinic Liver Cancer (BCLC) staging system 
(stage 0/A and B-D respectively). Levels of both biomarkers were compared in all groups. Predictive yield of both 
biomarkers for early HCC was evaluated using ROC curve analysis. 
Results. Level of sCD25 was significantly higher in patients with HCC than in both cirrhotic controls and 
healthy controls (P<0.0001and 0.013 respectively). For prediction of early HCC in patients with cirrhosis, the 
optimal sCD25 cut-off level was 7.15 ng/ml with sensitivity and specificity of 90% and 60% respectively (AUC=0.717; 
P=0.019) while sensitivity and specificity of AFP were 70% and 85% respectively at a cut-off value of 9.85 ng/ml 
(AUC=0.781; P=0.002) in the same settings. 
Conclusion. sCD25 seems to be a reliable biomarker for early detection of HCC and therefore could enhance 
the outcome. 
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Introduction
Hepatocellular carcinoma is one of the most 
serious and life threatening complications of 
chronic liver disease. It represents the 5th most 
common malignancy in men, the 7th in women 
and the 3rd malignancy related mortality world-
wide. Curative treatment strategy can be achie-
ved if detected in early stages [1–4]. The role of 
serum α­fetoprotein (AFP), the widely used 
classical biomarker for HCC, has been stepped 
down in the recent European and American 
surveillance guidelines because of low sensitivity 
and specificity. This is based on the knowledge 
that almost 80% of small HCCs do not show 
increased levels of AFP, and the sensitivity 
decreases to 25% in tumors smaller than 3 cm 
[5–8]. Looking for a new marker with a better 
diagnostic accuracy became an inevitable re-
qui rement. This eventually would optimize the 
HCC surveillance program and improve the 
outcome through prompt application of the 
proper treatment strategy early in the course 
of the disease. Serum soluble CD25 (sCD25) has 
been recently investigated as a new marker for 
hepatocellular carcinoma. It quantitatively 
reflects the immunological activity against the 
tumor [9–11]. It represents the α­chain of inter­
leukin 2 receptor (IL­2Rα) which is composed 
of three polypeptide chains: α, β and γ. It is not 
found on the surface of resting T cells, but 
rapidly expressed on their surface after being 
activated. Chronic T-cell stimulation, as in some 
malignancies, leads to shedding of IL­2Rα 
(CD25) into plasma with subsequent elevation 
of its level [11–16]. Cabrena and colleagues 
reported that serum level of sCD25 was corre-
lating with tumor burden and poor survival in 
HCC patients and believed that measuring 
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serum level of sCD25 might provide a clue for 
early diagnosis of HCC [12]. When we designed 
the current study, we hypothesized that sCD25 
could have an impressive diagnostic value and 
a potential ability for detection of early HCC. 
We assessed the performance of sCD25 in the 
prediction of early HCC and its correlation with 
the tumor stage and compare it with AFP.
Methods
The study was conducted in National Liver 
Institute, Menoufiya, Egypt. After obtaining an 
informed consent, eighty persons in 3 groups 
were included; HCC on a background of cirrho-
sis (40 patients), liver cirrhosis with no evidence 
of HCC (20 patients) and healthy control group 
(20 patients). HCC group comprised 20 early 
and 20 late stage HCC patients, according to 
Barcelona Clinic Liver Cancer (BCLC) staging 
system, (stage A and B-D respectively) (Fig. 1). 
Cirrhotic and healthy controls had matched age 
and sex with HCC patients. All included cases 
of HCC was diagnosed on the basis of the 
presence of typical vascular enhancement 
pattern of liver lesion (s) in contrast enhanced 
dynamic CT scan or MRI [18]. Diagnosis of 
cirrhosis was based on combined historical, 
clinical, laboratory and radiological findings. 
Severity of cirrhosis was assessed by Child Pugh 
classification [19]. All patients had complete 
laboratory profile including CBC, liver panel, 
creatinin as well as serum level of sCD25 and 
AFP. ELISA kit (Elecsys E411, Switzerland) was 
used to quantify blood level of AFP while ELISA 
kit (Bender MedSystems, Vienna, Austaria) was 
used to measure serum level of sCD25.
Statistical methods
SPSS, version 21 for Windows (Inc, Chicago, 
IL, USA) was used for all statistical analyses. 
Qualitative data were presented as frequency 
and percentage. Chi square and Fisher’s exact 
tests were used to compare groups. Quantitative 
data were presented as mean and standard 
deviation. For non-parametric data, Student 
t-test and Mann–Whitney U test were used to 
compare level difference of sCD25 between two 
groups while ANOVA and Kruskal Wallis were 
used to compare level difference of sCD25 
between more than two groups. Receiver-ope-
rator characteristic (ROC) curve analysis was 
used to generate sensitivity and specificity at 
different cut-offs. The best cut-off was set at 
the value where sensitivity and specificity were 
maximal. Correlation between serum level of 
sCD25 and laboratory parameters was assessed 
by Spearman's correlation coefficient. The sta­
tistical significance was set at P­value of less 
than 0.05 for all tests.
Results
The studied populations were mostly males 
representing 77.5, 75 and 60% in HCC, cirrhotic 
and healthy control groups respectively. The 
mean age was 56.38±5.934 years in HCC group 
while was 53.75±7.383 and 54.20±5.863 years in 
cirrhotic and healthy controls respectively. 
Hepatitis c virus (HCV) was the underlying 
etiology of cirrhosis in all patients in both HCC 
and cirrhotic control groups. The mean sCD25 
level was 13.07±6.645, 13.15±6.967, 8.938±6.487 
and 4.97±3.031 ng/ml in early HCC, late HCC, 
cirrhotic and healthy control groups respectively. 
Level of sCD25 was significantly higher in 
patients with HCC than in both cirrhotic and 
healthy controls (p<0.0001 and 0.013 respec ti-
vely) and significantly higher in cirrhotic pa­
tients than healthy controls (p=0.042). sCD25 
level was significantly and positively correlated 
with the severity of liver disease as assessed by 
Child-Pugh classification (r=0.56, p<0.001). 
There was no statistical difference between 
sCD25 in early and late HCC (p=0.968). The 
mean AFP level was 17.66±12.092, 244±302.041, 
8.01±6.965 and 2.95±2.175 ng/ml in early HCC, 
Fig. 1. Barcelona Clinic Liver Cancer (BCLC) staging and treatment strategy (Adapted from Llovet JM, et al. Lancet 2003) 
[17]. PS – performance status; PEI – percutaneous ethanol injection; RF – radiofrequency
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Table 1. Statistical difference of demographic and laboratory data  
among the studied groups
AFP – α­fetoprotein; Hb – hemoglobin; HCC – hepatocellular carcinoma; INR – international normalized ratio; LC – liver 
cirrhosis; NA – not applicable; p – significance between HCC and healthy controls; p* – significance between liver cirrhosis 
and healthy controls; p^ – significance between HCC and liver cirrhosis; p# – significance between early and late HCC; 
sCD25 – soluble CD25; ♂s – males; ♀s – females.
Table 2. Correlation between sCD25 and laboratory parameters  
among the studied groups
Total HCC
(n=40)
Early HCC
(n=20)
Late HCC
(n=20)
LC
(n=20)
Control
(n=20)
r p r p r p r p r p
Hb (g/dl) -0.060 0.714 -0.038 0.875 0.040 0.866 0.304 0.193 -0.371- 0.118
WBCs (×103/dl) -0.228 0.157 -0.478 0.033 -0.063 0.792 -0.081 0.736 0.179 0.462
Platelets (×103/dl) 0.128 0.431 0.068 0.777 0.290 0.215 -0.136 0.567 -0.269 0.265
INR 0.151 0.352 0.250 0.287 0.039 0.869 -0.224 0.343 0.035 0.887
Albumin (g/dl) 0.002 0.991 0.205 0.387 -0.220 0.352 0.142 0.550 0.064 0.794
Bilirubin (mg/dl) -0.038 0.816 -0.102 0.668 -0.021 0.928 -0.442 0.051 0.266 0.270
ALT (U/ml) 0.093 0.570 0.078 0.745 0.049 0.838 -0.014 0.955 0.348 0.144
AST (U/ml) 0.124 0.445 0.179 0.450 0.078 0.744 -0.078 0.744 0.390 0.099
Creatinin (mg / dl) 0.062 0.706 0.136 0.569 -0.043 0.856 -0.217 0.359 -0.249 0.303
AFP (ng/ml) 0.023 0.890 0.196 0.407 -0.093 0.697 -0.254 0.279 0.503 0.028
Total 
HCC
(n=40)
Early 
HCC
(n=20)
Late HCC
(n=20)
LC
(n=20)
Healthy 
control
(n=20)
p p* p^ p#
Sex
n (%)
♂s 31 (77.5) 15 (75) 16 (80) 15 (75) 12 (60) 0.156 0.311 0.829 0.705♀s 9 (22.5) 5 (25) 4 (20) 5 (25) 8 (40)
Age (years) Mean±SD
0.212 0.822 0.133 0.53956.38±
5.934
58.40±
5.576
55.35±
5.706
53.75±
7.383
54.20±
5.863
Hb (g/dl) 11.07±
1.097
11.14±
1.268
11.01±
0.925
10.52±
0.928
12.71±
1.091 <0.001 <0.001 0.058 0.724
WBCs  
(×103/dl)
4.88±
1.717
5.18±
2.247
4.59±
0.903
4.87±
1.242
7.00±
1.693 <0.001 <0.001 0.977 0.282
Platelets  
(×103/dl)
119.65±
35.246
122.55±
34.264
116.75±
36.854
169.05±
31.749
217.80±
47.522 <0.001 <0.001 <0.001 0.609
INR 1.37±
0.196
1.43±
0.197
1.32±
0.185
1.31±
0.236
1.07±
0.081 <0.001 <0.001 0.225 0.091
Albumin (g/dl) 3.19±
0.371
3.334±
0.382
3.04±
0.299
3.55±
0.445
4.34±
0.463 <0.001 <0.001 0.002 0.009
Bilirubin  
(mg/dl)
1.64±
0.833
1.19±
0.415
2.09±
0.907
1.73±
0.692
0.84±
0.154 <0.001 <0.001 0.626 <0.001
ALT (U/ml) 65.15±
15.184
61.75±
17.278
68.55±
12.262
57.05±
10.655
24.45±
5.276 <0.001 <0.001 <0.001 0.159
AST (U/ml) 89.48±
24.724
76.50±
17.021
102.45±
24.708
67.85±
10.069
27.25±
4.962 <0.001 <0.001 0.019 <0.001
Creatinin  
(mg/dl)
0.93±
0.159
0.93±
0.180
0.94±
0.139
0.95±
0.161
1.04±
0.193 0.025 0.114 0.665 0.845
sCD25 
(ng/ml)
13.11±
6.719
13.07±
6.645
13.15±
6.967
8.938±
6.487
4.97±
3.031 <0.001 0.042 0.013 0.968
AFP (ng/ml) 130.83±
240.106
17.66±
12.092
244±
302.041
8.01±
6.965
2.95±
2.175 0.008 0.926 0.010 0.003
Child-Pugh 
score
n (%)
A 6 (15) 6 (30) 0 (0) 12 (60)
NA NA NA 0.001 0.004B 29 (72.5) 14 (70) 15 (75) 8 (40)
C 5 (12.5) 0 (0) 5 (25) 0 (0)
AFP – α­fetoprotein; Hb – hemoglobin; HCC – hepatocellular carcinoma; INR – international normalized ratio; LC – liver 
cirrhosis; r – Spearman’s correlation coefficient.
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late HCC, cirrhotic and healthy control groups 
respectively with statistical difference between 
HCC versus cirrhotics and early versus late HCC 
as well (p=0.010 and 0.003 respectively). The 
rest of demographic and laboratory data as well 
as their statistical differences between the stu-
died groups are presented in Table 1. Cor re-
lation analyses between sCD25 and laboratory 
parameters among the studied groups are 
presented in Table 2. There was no significant 
correlation with all laboratory parameters apart 
from a negative correlation with WBCs in early 
HCC group (r=-0.478, p=0.033) and a positive 
correlation with AFP in healthy control group 
(r=-0.503, p=0.028). sCD25 performed well in 
predicting HCC presence among patients with 
cirrhosis; sensitivity and specificity were 90% 
and 84.2% respectively at a cut-off value of 
7 ng/ml (AUC=0.969; p<0.0001). For prediction 
of early HCC in patients with cirrhosis, the 
optimal sCD25 cutoff level was 7.15 ng/ml with 
sensitivity and specificity of 90% and 60% 
respectively (AUC=0.717; p=0.019) while, 
sensitivity and specificity of AFP were 70% and 
85% respectively at a cut-off value of 9.85 ng/ml 
(AUC=0.781; p=0.002) in the same settings 
(Fig. 2).
Discussion
HCC represents the most serious and lethal 
complication of cirrhosis. Fortunately, early 
stages of HCC could be curative. Axiomatically, 
detection of HCC in early stages would be 
helpful in changing the poor outcome of late 
stages by offering the proper treatment early 
in the course of the disease with subsequent 
amelioration of the outcome [20–22]. In the 
current study, we evaluated the performance 
of sCD25 in predicting early HCC stages among 
patients with cirrhosis and compare it to AFP. 
Serum sCD25 level was significantly higher in 
HCC patients than cirrhotics (p<0.0001) and 
healthy controls (p=0.013). In the same stream, 
it was significantly higher in cirrhosis than 
healthy controls (p=0.042). Additionally, there 
was a significant positive correlation between 
serum sCD25 and severity of cirrhosis (Child-
Pugh class) (r=0.56, p<0.001). The optimal 
sCD25 cut-off level in detecting early HCC 
among cirrhotic patients was 7.15 ng/ml with 
sensitivity and specificity of 90% and 60% 
respectively (AUC=0.717; p=0.019). On the other 
hand, sensitivity and specificity of AFP were 70% 
and 85% respectively at a cut-off value of 
9.85 ng/ml (AUC=0.781; p=0.002) in the same 
settings .This higher sensitivity of sCD25 high-
lights its substantial role as a screening marker 
for HCC. Similar findings were reported by 
Cabrena and his group. They reported sCD25 
cut-off level of 2899 pg/ml as the best cut-off 
with a sensitivity of 89.6% and a specificity of 
39.3% (AUC=0.630, p<0.0001). By comparison, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Receiver operator curve (ROC) of sCD25 and AFP levels for the prediction of 
early HCC among patients with cirrhosis 
Fig. 2. Receiver operator curve (ROC) of sCD25 and AFP levels for the prediction of early HCC among patients 
with cirrhosis
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at a cut-off value of 20 ng/ml, AFP had a sen-
sitivity of 41.7% and a specificity of 82.6% 
(AUC=0.630, p=0.0257) [12] The difference 
between the optimal cuto-ff between the 
current study (7150 pg/ml) and that of Cabrena 
et al. (2899 pg/ml) might be referred to the 
variability in the sample size, underlying etio-
logy as well as dissimilarity in racial, ethnic, 
ge netic and environmental factors. It is note-
worthy that, the main underlying etiology of 
liver disease was HCV representing 92.5 and 
90% in HCC and cirrhosis groups respectively 
while 7.5 and 10% were referred to combined 
HCV and HBV etiology in the same groups res-
pectively. In the study of Cabrena et al., 60% 
were HCV, 13% were cryptogenic, 9% were 
alcoholic cirrhosis and 9% were non-alcoholic 
fatty liver disease (NAFLD) in HCC group while 
72% were HCV, 5% alcoholic cirrhosis and 5% 
NAFLD and 3% were cryptogenic in cirrhosis 
group. In spite of the presence of a significant 
positive correlation between serum levels of 
sCD25 and severity of liver cirrhosis, there was 
no significant difference in its level in early and 
late HCC which disclaims findings of Cabrena 
et al., who reported a significant positive 
correlation between serum levels of sCD25 and 
tumor stage [12]. We could not eventually find 
a reasonable explanation for these conflicting 
results however difference in underlying 
etiology, tumor differentiation/biology, inter-
racial and inter-ethnic variations between both 
studies might be accused. A notable finding 
that should be considered the correlation 
between sCD25 and AFP in HCC and cirrhosis 
groups was absent denoting that measuring 
both markers in serum can improve the recip-
rocally holistic diagnostic value of HCC.
Conclusions 
Serum sCD25 sounds to be a good marker 
for predicting early HCC. There was some 
discrepancy between the optimal cut-off in the 
current and previous studies. This calls for a 
large scale study for further integration and 
unification of the current results and previous 
ones and to standardize the optimal cut-off 
taking into consideration addressing the rela-
tionship between sCD25 level and tumor 
biology rather than tumor size and number. 
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